VITA 34 International AG: Diabetes Research Institute received IND approval for a clinical study in newly manifested Type 1 Diabetes children using autologous ‘Nabelschnurblut VITA34’
VITA 34 International AG / Regulatory Approval/Alliance Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Leipzig, August 11, 2008 - VITA 34 International AG (ISIN DE000A0BL849), the parent company of the leading private umbilical cord blood bank in the German-speaking countries VITA 34, received IND approval of its autologous Cord Blood for a clinical study in children with Type 1 Diabetes. The study will be performed by the Diabetes Research Institute of the Klinik und Poliklinik für Kinder- und Jugendmedizin of the Technical University Munich. A corresponding approval was granted by The Paul-Ehrlich-Institute, a high federal agency in Germany. The aim of the study is to investigate the safety and potential benefit of transfusing autologous Cord Blood in children who have newly manifested Type 1 Diabetes. The study is designed to last 24 months and will be controlled by a reference group. The risk of Type 1 Diabetes in Germany is about 1 in 600 by the age of fourteen. A similar pilot study in the USA shows promising results with regard to the disturbed immune balance, insulin requirements, and the quality of metabolic control. Press / Investor Relation: Axel Mühlhaus / Dr. Sönke Knop edicto GmbH Zeißelstraße 19 D-60318 Frankfurt Phone: +49 (069) 90550550 Fax : +49 (069) 90550577 eMail: vita34@edicto.de 11.08.2008 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: VITA 34 International AG Deutscher Platz 5a 04103 Leipzig Deutschland Phone: +49(0341)48792-40 Fax: +49(0341)48792-39 E-mail: info@vita34.de Internet: www.vita34.de ISIN: DE000A0BL849 WKN: A0BL84 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------